Patient preferences for the treatment of ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment.
Author(s) :
Bruni, C. [Auteur]
Heidenreich, S. [Auteur]
Duenas, A. [Auteur]
Hoffmann-Vold, A. M. [Auteur]
Gabrielli, A. [Auteur]
Allanore, Yannick [Auteur]
Hôpital Cochin [AP-HP]
Chatelus, Emmanuel [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Distler, J. H. W. [Auteur]
Hachulla, Eric [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hsu, V. M. [Auteur]
Hunzelmann, N. [Auteur]
Khanna, D. [Auteur]
Truchetet, Marie-Elise [Auteur]
CHU Bordeaux
Walker, U. A. [Auteur]
Alves, M. [Auteur]
Schoof, N. [Auteur]
Saketkoo, L. A. [Auteur]
Distler, O. [Auteur]
Heidenreich, S. [Auteur]
Duenas, A. [Auteur]
Hoffmann-Vold, A. M. [Auteur]
Gabrielli, A. [Auteur]
Allanore, Yannick [Auteur]
Hôpital Cochin [AP-HP]
Chatelus, Emmanuel [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Distler, J. H. W. [Auteur]
Hachulla, Eric [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hsu, V. M. [Auteur]
Hunzelmann, N. [Auteur]
Khanna, D. [Auteur]
Truchetet, Marie-Elise [Auteur]
CHU Bordeaux
Walker, U. A. [Auteur]
Alves, M. [Auteur]
Schoof, N. [Auteur]
Saketkoo, L. A. [Auteur]
Distler, O. [Auteur]
Journal title :
Rheumatology
Abbreviated title :
Rheumatology (Oxford)
Volume number :
61
Pages :
4035–4046
Publication date :
2022-03-05
ISSN :
1462-0332
English keyword(s) :
SSc
interstitial lung disease
patient preference
discrete choice experiment
interstitial lung disease
patient preference
discrete choice experiment
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objectives
Treatments for SSc-associated interstitial lung disease (SSc-ILD) differ in attributes, i.e. mode of administration, adverse events (AEs) and efficacy. As physicians and patients may perceive treatments ...
Show more >Objectives Treatments for SSc-associated interstitial lung disease (SSc-ILD) differ in attributes, i.e. mode of administration, adverse events (AEs) and efficacy. As physicians and patients may perceive treatments differently, shared decision-making can be essential for optimal treatment provision. We therefore aimed to quantify patient preferences for different treatment attributes. Methods Seven SSc-ILD attributes were identified from mixed-methods research and clinician input: mode of administration, shortness of breath, skin tightness, cough, tiredness, risk of gastrointestinal AEs (GI-AEs) and risk of serious and non-serious infections. Patients with SSc-ILD completed an online discrete choice experiment (DCE) in which they were asked to repeatedly choose between two alternatives characterized by varying severity levels of the included attributes. The data were analysed using a multinomial logit model; relative attribute importance and maximum acceptable risk measures were calculated. Results Overall, 231 patients with SSc-ILD completed the DCE. Patients preferred twice-daily oral treatments and 6–12 monthly infusions. Patients’ choices were mostly influenced by the risk of GI-AEs or infections. Improvement was more important in respiratory symptoms than in skin tightness. Concerning trade-offs, patients accepted different levels of increase in GI-AE risk: +21% if it reduced the infusions’ frequency; +15% if changing to an oral treatment; up to +37% if it improved breathlessness; and up to +36% if it reduced the risk of infections. Conclusions This is the first study to quantitatively elicit patients’ preferences for treatment attributes in SSc-ILD. Patients showed willingness to make trade-offs, providing a firm basis for shared decision-making in clinical practice.Show less >
Show more >Objectives Treatments for SSc-associated interstitial lung disease (SSc-ILD) differ in attributes, i.e. mode of administration, adverse events (AEs) and efficacy. As physicians and patients may perceive treatments differently, shared decision-making can be essential for optimal treatment provision. We therefore aimed to quantify patient preferences for different treatment attributes. Methods Seven SSc-ILD attributes were identified from mixed-methods research and clinician input: mode of administration, shortness of breath, skin tightness, cough, tiredness, risk of gastrointestinal AEs (GI-AEs) and risk of serious and non-serious infections. Patients with SSc-ILD completed an online discrete choice experiment (DCE) in which they were asked to repeatedly choose between two alternatives characterized by varying severity levels of the included attributes. The data were analysed using a multinomial logit model; relative attribute importance and maximum acceptable risk measures were calculated. Results Overall, 231 patients with SSc-ILD completed the DCE. Patients preferred twice-daily oral treatments and 6–12 monthly infusions. Patients’ choices were mostly influenced by the risk of GI-AEs or infections. Improvement was more important in respiratory symptoms than in skin tightness. Concerning trade-offs, patients accepted different levels of increase in GI-AE risk: +21% if it reduced the infusions’ frequency; +15% if changing to an oral treatment; up to +37% if it improved breathlessness; and up to +36% if it reduced the risk of infections. Conclusions This is the first study to quantitatively elicit patients’ preferences for treatment attributes in SSc-ILD. Patients showed willingness to make trade-offs, providing a firm basis for shared decision-making in clinical practice.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-01-12T02:09:36Z
2024-03-21T10:26:58Z
2024-03-21T10:26:58Z
Files
- keac126.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 3.0 United States